Aigen Investment Management LP Invests $1.36 Million in Gilead Sciences, Inc. (NASDAQ:GILD)

Aigen Investment Management LP acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 12,098 shares of the biopharmaceutical company’s stock, valued at approximately $1,356,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in GILD. Redwood Financial Network Corp lifted its position in shares of Gilead Sciences by 4.0% during the 4th quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company’s stock worth $234,000 after buying an additional 98 shares during the last quarter. Argentarii LLC lifted its position in shares of Gilead Sciences by 3.0% during the 1st quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company’s stock worth $380,000 after buying an additional 99 shares during the last quarter. Peak Financial Advisors LLC lifted its position in shares of Gilead Sciences by 1.7% during the 1st quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company’s stock worth $677,000 after buying an additional 100 shares during the last quarter. Perkins Coie Trust Co lifted its position in shares of Gilead Sciences by 2.6% during the 1st quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company’s stock worth $435,000 after buying an additional 100 shares during the last quarter. Finally, Investment Research & Advisory Group Inc. raised its position in Gilead Sciences by 33.3% in the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 100 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction dated Monday, June 30th. The shares were sold at an average price of $110.45, for a total value of $1,104,500.00. Following the sale, the chief executive officer directly owned 615,725 shares in the company, valued at $68,006,826.25. The trade was a 1.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total transaction of $277,575.00. Following the completion of the sale, the chief financial officer owned 162,610 shares in the company, valued at $18,054,588.30. This represents a 1.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 82,000 shares of company stock valued at $8,984,175. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD opened at $119.41 on Monday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The stock has a market capitalization of $148.17 billion, a P/E ratio of 23.79, a P/E/G ratio of 0.75 and a beta of 0.33. The company’s fifty day moving average is $110.93 and its two-hundred day moving average is $107.64. Gilead Sciences, Inc. has a 1 year low of $72.43 and a 1 year high of $121.38.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. During the same period in the prior year, the company posted $2.01 EPS. The business’s revenue for the quarter was up 1.4% on a year-over-year basis. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio is 62.95%.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Royal Bank Of Canada upped their price target on shares of Gilead Sciences from $96.00 to $98.00 and gave the company a “sector perform” rating in a research report on Friday. Needham & Company LLC upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price target for the company in a research report on Friday, July 25th. UBS Group upped their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research report on Friday. Truist Financial upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and upped their price target for the company from $108.00 to $127.00 in a research report on Friday. Finally, Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They issued an “overweight” rating and a $125.00 price target for the company. Seven investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $114.82.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.